Table 1.
Demographics and performance scores for study participants (n = 197) based on PsycH‐Q responses
| Negative | Positive | P Value | |
|---|---|---|---|
| Demographics | |||
| Number | 111 (56%) | 86 (44%) | |
| Age, years | 68.6 ± 8.4 | 70.5 ± 8.5 | n.s. |
| Duration, years | 7.2 ± 7.0 | 7.7 ± 6.3 | n.s. |
| Education, years | 14.0 ± 2.9 | 14.1 ± 3.3 | n.s. |
| MDS‐UPDRS III | 30.3 ± 15.6 | 34.5 ± 18.0 | n.s. |
| H&Y | 2.2 ± 0.9 | 2.2 ± 0.9 | n.s. |
| LEDD, mg/day | 720.6 ± 527.8 | 749.6 ± 583.5 | n.s. |
| MMSE | 28.2 ± 2.5 | 27.2 ± 3.7 | n.s. |
| Neuropsychological | |||
| BDI‐II | 7.5 ± 6.6 | 11.3 ± 10.1 | ** |
| PDQ‐39 | 31.7 ± 26.6 | 45.0 ± 28.4 | ** |
| PsycH‐Q | |||
| Visual Misperceptions scorea | 0.0 ± 0 | 4.5 ± 5.0 | *** |
| Sensory Misperceptions scorea | 0.0 ± 0 | 1.4 ± 2.5 | *** |
| Thought Disorder scorea | 0.0 ± 0.0 | 0.5 ± 1.5 | *** |
| Attention Dysfunction scorea | 3.3 ± 3.8 | 6.8 ± 4.4 | *** |
| Sleep Impairment scorea | 1.5 ± 1.6 | 3.2 ± 2.5 | *** |
| Total severity scorea | 22.3 ± 3.0 | 28.5 ± 8.6 | *** |
Patients were split into two groups (Negative and Positive) depending on whether they reported positive symptoms on Section I of the PsycH‐Q.
Statistical significance (Bonferroni adjusted t‐test of means): **P < 0.01; ***P < 0.001; n.s., P > 0.05.
a
Kruskall‐Wallis test used for non‐parametric data.
LEDD, levo‐dopa equivalent daily dose.